Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Nora, Ku"'
Autor:
Valentina Nardi, Nora Ku, Matthew J. Frigault, Adrian M. Dubuc, Harrison Kwei Tsai, Philip C. Amrein, Gabriela S. Hobbs, Andrew M. Brunner, Rupa Narayan, Meghan E. Burke, Julia Foster, Paola Dal Cin, Marcela V. Maus, Amir T. Fathi, Hanno Hock
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 106-111 (2020)
Abstract: Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a subtype of Ph-negative ALL that molecularly resembles Ph-positive ALL. It shares the adverse prognosis of Ph-positive ALL, but lacks the BCR-ABL1 fusion oncogene. I
Externí odkaz:
https://doaj.org/article/7fc7238856444e36b2853dd5b133bf4f
Autor:
David M. Hyman, S. Michael Rothenberg, Steve Andrews, Barry S. Taylor, Jaclyn F. Hechtman, Michael F. Berger, Philip Jonsson, Alison M. Schram, Bethany Hanusch, Sandeep Raj, Ryma Benayed, Maurizio Scaltriti, Dorothea N. Douglas-Lindsay, Paul R. Gordon, Lance A. Wollenberg, Walter E. DeWolf, Francis X. Sullivan, Tony H. Morales, Andrew Parker, Wen-I Wu, Robyn Hamor, Shannon L. Winski, Karyn S. Bouhana, Paul D. Larsen, Barbara J. Brandhuber, Gabrielle R. Kolakowski, Veronique Lauriault, Steve Smith, Kevin Ebata, Brian B. Tuch, Nora Ku, James F. Blake, Ramamoorthy Nagasubramanian, Alexander Drilon
Supplementary Methods Supplementary References Supplementary Figure 1. Effect of acquired resistance mutations on TRK inhibitor activity. Supplementary Figure 2. Further characterization of LOXO-195 inhibitory activity against acquired resistance mut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5cf7abc92430333d360a2e3d9ce4f70
https://doi.org/10.1158/2159-8290.22532260
https://doi.org/10.1158/2159-8290.22532260
Autor:
Steven Le Gouill, Nora Ku, Chan Yoon Cheah, Binoj Nair, Jennifer A. Woyach, Minal A. Barve, Timothy S. Fenske, John M. Pagel, Alvaro J. Alencar, M. Lia Palomba, Ian W. Flinn, Catherine C. Coombs, Bita Fakhri, David John Lewis, Nirav N. Shah, Paolo Ghia, Toby A. Eyre, Michael Wang, Donald E. Tsai, James N. Gerson, Anthony R. Mato, Katharine L Lewis, Manish R. Patel, Jonathon B. Cohen, Nicole Lamanna, Ming Yin, Xuan Ni Tan, Wojciech Jurczak
Publikováno v:
Blood. 136:8-10
Background: Covalent BTK inhibitors (BTKi) have transformed the management of MCL, WM, and MZL. Despite the marked efficacy of covalent BTKi, treatment failure can occur through the development of resistance and discontinuation for adverse events. Co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba8c971f9b60304dcf13579b58c485f6
https://doi.org/10.1182/blood-2020-134314
https://doi.org/10.1182/blood-2020-134314
Autor:
James N. Gerson, John M. Pagel, Toby A. Eyre, Lindsey E. Roeker, Manish R. Patel, Catherine C. Coombs, Nirav N. Shah, Jessica A. Chen, Paolo Ghia, Nora Ku, Jennifer R. Brown, Jennifer A. Woyach, Minal A Barve, Bita Fakhri, David John Lewis, Alvaro J. Alencar, Constantine S. Tam, Ewa Lech-Marańda, Omar Abdel-Wahab, Chan Yoon Cheah, Binoj Nair, Matthew S. Davids, Donald E. Tsai, Justin Taylor, Anthony R. Mato, Wojciech Jurczak, Stephen J. Schuster, Nicole Lamanna, William G. Wierda
Publikováno v:
Blood. 136:35-37
Background: Covalent BTK inhibitors (BTKi) have transformed the management of CLL/SLL. Despite the marked efficacy of covalent BTKi, treatment failure can occur through the development of resistance and discontinuation for adverse events. The activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5dd61a950198ca01d040af0e54d22258
https://doi.org/10.1182/blood-2020-134970
https://doi.org/10.1182/blood-2020-134970
Autor:
Alexander Drilon, A Onitilo, Neerav Shukla, Funda Meric-Bernstam, S Montez, Nora Ku, David S. Hong, Nir Peled, Y Landman, David M. Hyman
Publikováno v:
Cancer Research. 79:P6-20
Background: Tropomyosin receptor kinase (TRK fusions) involving the genes NTRK1, NTRK2, and NTRK3 occur in a broad range of malignancies including breast cancers (BC) with secretory features. Larotrectinib, the first selective TRK inhibitor in clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2505170ee1816f386f51cabaaeb02d27
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-02
https://doi.org/10.1158/1538-7445.sabcs18-p6-20-02
Autor:
Vijaya G Tirunagaru, Feng Xu, Trista Hinz, Lynn Heasley, Richard Bryce, Avanish Vellanki, Nora Ku, Robert Charles Doebele
Publikováno v:
Journal of Clinical Oncology. 40:3136-3136
3136 Background: MDM2 is an E3 ubiquitin ligase that plays a critical role in the degradation of the tumor suppressor p53. Milademetan (RAIN-32) is an orally available, small molecule inhibitor of MDM2 that disrupts the MDM2-p53 complex thereby resto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::932bb7a1b49cdf0d3d12a00a0a0e8d23
https://doi.org/10.1200/jco.2022.40.16_suppl.3136
https://doi.org/10.1200/jco.2022.40.16_suppl.3136
Autor:
Ming Yin, Edward Y. Zhu, Justin Taylor, Michael Wang, Anthony R. Mato, Matthew S. Davids, Nora Ku, Lindsey E. Roeker, Ian W. Flinn, Jennifer A. Woyach, Johan Wallin, Nicole Lamanna, Timothy S. Fenske, Donald E. Tsai, Steven Le Gouill, Suchitra Sundaram, David J. Lewis, John M. Pagel, Toby A. Eyre, Catherine C. Coombs, Stephen J. Schuster, Kevin Ebata, Xuan Ni Tan, Manish R. Patel, Jonathon B. Cohen, Narasimha Marella, Katharine L Lewis, Chan Yoon Cheah, Omar Abdel-Wahab, Bita Fakhri, Binoj Nair, Bryone J. Kuss, M. Lia Palomba, Constantine S. Tam, Alvaro J. Alencar, Wojciech Jurczak, Nirav N. Shah, James N. Gerson, Jennifer R. Brown, Paolo Ghia, Ewa Lech-Marańda, Minal A Barve, Jessica A. Chen, William G. Wierda
Publikováno v:
The Lancet
The Lancet, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩
Lancet
Lancet, Elsevier, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩
The Lancet, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩
Lancet
Lancet, Elsevier, 2021, 397 (10277), pp.892-901. ⟨10.1016/S0140-6736(21)00224-5⟩
International audience; Background: Covalent Bruton's tyrosine kinase (BTK) inhibitors are efficacious in multiple B-cell malignancies, but patients discontinue these agents due to resistance and intolerance. We evaluated the safety and efficacy of p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec4facff70af93a082c78985f5284f1e
https://ruj.uj.edu.pl/xmlui/handle/item/290422
https://ruj.uj.edu.pl/xmlui/handle/item/290422
Autor:
Maria E. Arcila, Emiliano Cocco, Maurizio Scaltriti, Eli L. Diamond, Lee A. Albacker, Christina Marcelus, Brian B. Tuch, Justin Taylor, Stephen S. Chung, Kevin Ebata, Dean Pavlick, Ryma Benayed, Young Rock Chung, Omar Abdel-Wahab, Benjamin H. Durham, Jaclyn F. Hechtman, Nora Ku, David M. Hyman, Mikhail Roshal, Kerry Mullaney, Siraj M. Ali, Lillian Bitner, Tariq I. Mughal, Akihide Yoshimi, Daichi Inoue, Justin M. Watts, Jae H. Park
Publikováno v:
Journal of Clinical Investigation. 128:3819-3825
Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. Although TRK fusions occur in fewer than 1% of all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89485bd74d880713ae19be9b733d4660
https://doi.org/10.1172/jci120787
https://doi.org/10.1172/jci120787
Autor:
Maxim Yakimov, Nir Peled, Yosef Landman, Siraj M. Ali, Maya Ilouze, Simon Wein, Rinat Yerushalmi, Victoria Neiman, Nora Ku, Alexa B. Schrock
Publikováno v:
Clinical Breast Cancer. 18:e267-e270
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde03643948adcdac77c46dca0533478
https://doi.org/10.1016/j.clbc.2017.11.017
https://doi.org/10.1016/j.clbc.2017.11.017
Autor:
Steven G. DuBois, Michael J. Nathenson, John F. Deeken, Anna F. Farago, Luis E. Raez, Alberto S. Pappo, Ryma Benayed, Alexander Drilon, Funda Meric-Bernstam, Christina S. Baik, Brian B. Tuch, David M. Hyman, Valentina Boni, Noah Federman, Marcia S. Brose, Ulrik Lassen, Douglas S. Hawkins, Kevin Ebata, Nora Ku, Jordan Berlin, Scott Cruickshank, Leo Mascarenhas, Theodore W. Laetsch, Brian Turpin, George D. Demetri, Afshin Dowlati, Patrick C. Ma, Shivaani Kummar, David S. Hong, Robert C. Doebele, Jaclyn F. Hechtman, Ramamoorthy Nagasubramanian, Davendra Sohal, Matthew H. Taylor, Michael C. Cox, Wafik S. El-Deiry, Marc Ladanyi, Erin R. Rudzinski
Publikováno v:
The New England journal of medicine, vol 378, iss 8
BackgroundFusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8038e7eee9bf93284d85c198521865a4
https://doi.org/10.1056/nejmoa1714448
https://doi.org/10.1056/nejmoa1714448